Literature DB >> 10480212

Neuroaxonal dystrophy with dystonia and pallidal involvement.

A Simonati1, C Trevisan, A Salviati, N Rizzuto.   

Abstract

Infantile neuroaxonal dystrophy (INAD) is an autosomal recessive disease of infantile onset, characterised by progressive clinical course, multi-systemic involvement and widespread presence of dystrophic axons in both the central and peripheral nervous system. Clinical, neurophysiological and neuroradiological criteria of the disease are established, but the occurrence of atypical cases is known. Since the availability of molecular markers is still lacking, diagnostic evidence in vivo is provided by the presence of specific axonal lesions distally in the peripheral nerve fibres. In two children who had a protracted course of the disease with dystonic postures of the upper limbs and showed dystrophic axons following sural nerve biopsy, bilateral pallidal hypointensity was observed after T2-weighted MRI scans. These findings are consistent with iron deposition, and are usually observed in Hallervorden-Spatz syndrome (HSS), a condition which is also characterised by dystrophic axons diffusely present in the central nervous system, but without peripheral nervous system involvement. These observations raise the issue of different phenotypes of INAD, and are consistent with the existence of intermediate forms between INAD and HSS. Altered mechanisms of iron storage and transport to and from the cellular compartments may play a role in the pathogenesis of the disease.

Entities:  

Mesh:

Year:  1999        PMID: 10480212     DOI: 10.1055/s-2007-973482

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  4 in total

1.  Diffusion-weighted and conventional MR imaging findings of neuroaxonal dystrophy.

Authors:  R Nuri Sener
Journal:  AJNR Am J Neuroradiol       Date:  2004-08       Impact factor: 3.825

2.  Neurodegeneration associated with genetic defects in phospholipase A(2).

Authors:  A Gregory; S K Westaway; I E Holm; P T Kotzbauer; P Hogarth; S Sonek; J C Coryell; T M Nguyen; N Nardocci; G Zorzi; D Rodriguez; I Desguerre; E Bertini; A Simonati; B Levinson; C Dias; C Barbot; I Carrilho; M Santos; I Malik; J Gitschier; S J Hayflick
Journal:  Neurology       Date:  2008-09-17       Impact factor: 9.910

3.  PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron.

Authors:  Neil V Morgan; Shawn K Westaway; Jenny E V Morton; Allison Gregory; Paul Gissen; Scott Sonek; Hakan Cangul; Jason Coryell; Natalie Canham; Nardo Nardocci; Giovanna Zorzi; Shanaz Pasha; Diana Rodriguez; Isabelle Desguerre; Amar Mubaidin; Enrico Bertini; Richard C Trembath; Alessandro Simonati; Carolyn Schanen; Colin A Johnson; Barbara Levinson; C Geoffrey Woods; Beth Wilmot; Patricia Kramer; Jane Gitschier; Eamonn R Maher; Susan J Hayflick
Journal:  Nat Genet       Date:  2006-06-18       Impact factor: 38.330

Review 4.  New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases.

Authors:  Marco T Nuñez; Pedro Chana-Cuevas
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.